Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02451826
Recruitment Status : Unknown
Verified August 2017 by Population Council.
Recruitment status was:  Active, not recruiting
First Posted : May 22, 2015
Last Update Posted : August 15, 2017
Sponsor:
Information provided by (Responsible Party):
Population Council

Brief Summary:
The purpose of this study is to determine the effect of a contraceptive vaginal ring on inhibition of ovulation, endometrial changes and bleeding patterns in normal cycling women.

Condition or disease Intervention/treatment Phase
Ovulation Inhibition Drug: Ulipristal acetate Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering a Daily Dose of 2500 μg of Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel 1.5mg Oral Dose on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women
Study Start Date : May 2015
Estimated Primary Completion Date : November 1, 2017
Estimated Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Active Comparator: 1.5 mg tablet LNG after 12 weeks
CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
Drug: Ulipristal acetate
CVR delivering Ulipristal acetate and one tablet levonorgestrel.

Active Comparator: 1.5 mg tablet LNG every 4 weeks
CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
Drug: Ulipristal acetate
CVR delivering Ulipristal acetate and one tablet levonorgestrel.




Primary Outcome Measures :
  1. Pharmacodynamic efficacy as measured by the effects of a vaginal ring delivering Ulipristal acetate consistently combined with levonorgestrel administration on the endometrium [ Time Frame: 3 months ]
    Endometrial biopsies (EB) will be taken as follows, a.During the follicular phase (between Day 9 and Day 12) of the baseline/control cycle, b. At the end of the 14th week of treatment (14 days after the 12 week LNG administration and end of CVR use), c. During the follicular phase (between Day 9 and Day 12 of the second menstrual cycle after ring removal). Also, endometrial changes will be measured by histological examination, immunohistochemistry, and assessment of proliferation markers (Ki67, Phospho H3 and bcl2).


Secondary Outcome Measures :
  1. Safety as measured by number of participants with occurrence of adverse events (AEs) and concomitant medication use [ Time Frame: 3 months ]
    Safety as measured by the assessment of a vaginal ring delivering Ulipristal acetate consistently combined with levonorgestrel administration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Not at risk for pregnancy based on one of the following: a. subject has undergone sterilization; b. subject is monogamous and her male partner has undergone sterilization
  • Have regular menstrual cycles of 25-35 days duration
  • Have an intact uterus and both ovaries
  • Will be able to comply with the protocol
  • Capable of giving informed consent

Exclusion Criteria:

  • Women participating in another clinical trial
  • Women not living in the catchment area of the clinic
  • Known hypersensitivity to progestins or antiprogestins
  • Known hypersensitivity to silicone rubber
  • Any chronic disease
  • All contraindications to oral contraceptive use, including: a. Thrombophlebitis or thromboembolic disorders; b. Past history of deep vein thrombophlebitis or thromboembolic disorders; c. Past or current cerebrovascular or coronary artery disease; d. Migraine with focal aura; e. Known or suspected carcinoma of the breast; f. Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia; g. Undiagnosed abnormal genital bleeding; h. Cholestatic jaundice of pregnancy or jaundice with prior pill use; i. Hepatic adenomas or carcinomas; j. Known or suspected pregnancy
  • Desire to get pregnant during the study (through the use of reproductive technology for sterilized women or vasectomy reversal for sterilized partners)
  • Breastfeeding
  • Undiagnosed vaginal discharge or vaginal lesions or abnormalities
  • Women with a current abnormal Pap: In accordance with the Bethesda system of classification: smear suggestive of high-grade pre-cancerous lesion(s), including HGSIL, are excluded; Women with LGSIL or ASCUS/high-risk HPV positive may participate if further evaluated with colposcopy and biopsy and no evidence of a lesion with a severity > CIN I is present and/or endocervical curettage is negative; Women with a biopsy finding of CIN I should have follow up for this finding per standard of care; women are excluded it treatment is indicated.
  • Known benign or malignant liver tumors; known active liver disease
  • Cancer (past history of any carcinoma or sarcoma)
  • Medically diagnosed severe depression currently or in the past
  • Known or suspected alcoholism or drug abuse
  • Abnormal serum fasting clinical chemistry values
  • Women with known abnormal thyroid status
  • Women with known impaired hypothalamic-pituitary-adrenal reserve
  • Average diastolic BP > 85 mm or systolic BP >135 mm Hg after 5-10 minutes rest
  • Body mass index (BMI) > 30.0 (or ≤18)
  • Smoking in women who will be 35 years during the course of the trial; women < 35 years who smoke greater than 15 cigarettes per day must be evaluated by the PI for inclusion based on risk factors that would increase their risk for CVD and thromboembolism, e.g. lipid levels, glucose level, BP, BMI, family history of CVD at a young age.
  • Women with severe cystoceles or rectoceles
  • Use within the past 2 months of any implanted hormonal contraceptives including Mirena [progestin containing intrauterine system (IUS)] or Norplant (subdermal implant delivering LNG). NOTE: Removal of implanted hormonal contraceptives must have been for personal reasons unrelated to the purpose of enrollment in this study.
  • Current use of a non-hormone containing IUD. NOTE: Removal of an IUD must have been for personal reasons unrelated to the purpose of enrollment in this study.
  • Use of injectable contraceptives during the previous 3 months (e.g. Cyclofem) or 6 months (e.g. DMPA).
  • Women who do not have at least two progesterone measurements during the control cycle of ≥10nmol/L will be excluded from further participation in the study (See Section 13.4.1)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02451826


Locations
Layout table for location information
Dominican Republic
Profamilia
Santo Domingo, Dominican Republic
Sponsors and Collaborators
Population Council
Investigators
Layout table for investigator information
Study Director: Ruth Merkatz, Ph.D. Population Council

Layout table for additonal information
Responsible Party: Population Council
ClinicalTrials.gov Identifier: NCT02451826     History of Changes
Other Study ID Numbers: 674
First Posted: May 22, 2015    Key Record Dates
Last Update Posted: August 15, 2017
Last Verified: August 2017
Keywords provided by Population Council:
ovulation inhibition
endometrial changes
bleeding patterns
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhage
Pathologic Processes
Contraceptive Agents
Levonorgestrel
Ulipristal acetate
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral